BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...past five years.Shanghai Genechem Co. Ltd. and I-Mab Biopharma (NASDAQ:IMAB...
...– Tumor antigen MG7 BC Staff Shanghai Genechem Co. Ltd. I-Mab Biopharma...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...Cranmer discuss what last week’s deal with I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Mar 10, 2021
Deals

I-Mab signs first two deals of immuno-oncology discovery initiative

...the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline. I-Mab Biopharma (NASDAQ:IMAB...
...in addition to an internal preclinical bispecific platform that’s focused on immunotherapy targets for cancer. Stephen Hansen I-Mab Biopharma Complix...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Antibody-drug conjugate targeting CLDN6 for liver cancer

DISEASE CATEGORY: Cancer INDICATION: Liver cancer An antibody-drug conjugate targeting the tight junction protein CLDN6 could treat hepatocellular carcinoma (HCC). In patients, high tumor levels of CLDN6 protein were associated with poor overall and disease-free...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...these groups, two also have their compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...CBC has been a key investor in cross-border licensing company Everest Medicines Ltd. (HKEX:1952); I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Dec 8, 2020
Politics, Policy & Law

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

...point,” Lin added.  At the 7th China Healthcare Summit hosted by BioCentury-BayHelix last month, I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...conducting a Phase II U.S. trial of the mAb, to which it has ex-China rights.I-Mab Biopharma (NASDAQ:IMAB...
...Optical won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang Li I-Mab Biopharma Jiangsu...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Inc. (NASDAQ:ALXO), Gilead Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB...
...alpha constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...& Co., who cited recent out-licensing deals by I-Mab Biopharma (NASDAQ:IMAB...
...MediTech Ltd. Sofinnova Partners Hua Medicine Ltd. CStone Pharmaceuticals Co. Ltd. I-Mab Biopharma Qiming...
Items per page:
1 - 10 of 95
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...past five years.Shanghai Genechem Co. Ltd. and I-Mab Biopharma (NASDAQ:IMAB...
...– Tumor antigen MG7 BC Staff Shanghai Genechem Co. Ltd. I-Mab Biopharma...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...Cranmer discuss what last week’s deal with I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Mar 10, 2021
Deals

I-Mab signs first two deals of immuno-oncology discovery initiative

...the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline. I-Mab Biopharma (NASDAQ:IMAB...
...in addition to an internal preclinical bispecific platform that’s focused on immunotherapy targets for cancer. Stephen Hansen I-Mab Biopharma Complix...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Antibody-drug conjugate targeting CLDN6 for liver cancer

DISEASE CATEGORY: Cancer INDICATION: Liver cancer An antibody-drug conjugate targeting the tight junction protein CLDN6 could treat hepatocellular carcinoma (HCC). In patients, high tumor levels of CLDN6 protein were associated with poor overall and disease-free...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...these groups, two also have their compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...CBC has been a key investor in cross-border licensing company Everest Medicines Ltd. (HKEX:1952); I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Dec 8, 2020
Politics, Policy & Law

Data Byte: NASDAQ’s Chinese biotechs may look to Hong Kong for secondary listings as House passes auditing bill

...point,” Lin added.  At the 7th China Healthcare Summit hosted by BioCentury-BayHelix last month, I-Mab Biopharma (NASDAQ:IMAB...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...conducting a Phase II U.S. trial of the mAb, to which it has ex-China rights.I-Mab Biopharma (NASDAQ:IMAB...
...Optical won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang Li I-Mab Biopharma Jiangsu...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Inc. (NASDAQ:ALXO), Gilead Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB...
...alpha constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...& Co., who cited recent out-licensing deals by I-Mab Biopharma (NASDAQ:IMAB...
...MediTech Ltd. Sofinnova Partners Hua Medicine Ltd. CStone Pharmaceuticals Co. Ltd. I-Mab Biopharma Qiming...
Items per page:
1 - 10 of 95